Tempus AI is a second- or third-tier genomic lab whose AI story is marketing mumbo jumbo, and its management team are promoters. x.com 

Tempus AI deserves a management-quality discount because of governance and credibility risk around Lefkofsky, not established medical malpractice. His history, including his Groupon tenure, how Tempus acquired Ambry, and unresolved allegations mean it should not be treated as a clean long-term compounder until cash flow, AI-derived revenue and related-party disclosures become much clearer. The stock may still trade well technically. x.com 

Tempus AI's selloff after it beat and raised guidance looks like a great deal, and a further drop would be a chance to buy more. x.com 

Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.com 

Tempus AI's 2025 growth was less impressive than it looks: only half was organic, with the other half coming from the Ambry acquisition. x.com 

Tempus AI's thesis remains intact after objectively strong earnings and a guidance raise. It looks less threatened by Anthropic than other software names because its datasets form its moat, for now. Software multiples remain a big question, and these stocks are struggling to catch a break, but the technical setup still looks good despite the pullback. x.com 

Tempus AI may go lower near term because of valuation, leadership reputation and insider selling, despite an amazing business. With about 25% growth expected and profitability uncertain, it is not obviously cheap. Glassdoor reviews matter in medicine's high-trust setting, and ongoing insider sales echo founder patterns that ended badly. The data piece, about 5% of market cap, can earn a high multiple, so the stock looks reasonably priced if adoption continues. x.com 

AI-for-science stocks show a typical pump-and-dump setup driven by Chinese and Hong Kong hedge funds, and more pumps and dumps are likely. These funds trade narratives and price in an extremely bright future, so consensus forms fast and crowded positions reverse easily. When Chinese sell-side analysts or the Chinese community on X are loud about a thesis, it is a trade to avoid. Fundamentals still look exciting, and key moving averages are the signal to re-enter long. x.com  x.com 

Tempus AI could catch a bid as a laggard in the hot medical AI space, and it could catch fire soon. Its setup is getting too hard to ignore, despite plenty of past scars on the name. x.com  x.com  x.com 

QuantumScape is less attractive than Tempus AI because it is still pre-commercial and burning a lot of cash. x.com